Tag: Breast Cancer

Figure 4: Loss of p53 predisposes to mammary tumors in mice and in women, but penetrance varies among individuals.

Genetic Modifiers of p53 and Their Potential in Breast Cancer Therapies

October 25, 2023

“[...] p53 acts in concert with other genes that alter the penetrance of tumor phenotypes and the modifiers differ among tissues.” BUFFALO, NY- October 25, 2023 – A new editorial… read more

Figure 1: Working model for TME-mediated nuclear softening via LINC and emerin.

Oncotarget

The Nuclear Envelope and Breast Cancer Metastasis

October 18, 2023

“[...] ascertaining the mechanisms that enable metastatic spread can be transformational in our understanding of tumor progression and for future development of therapeutic interventions.” BUFFALO, NY- October 18, 2023 –… read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” BUFFALO, NY- September 13, 2023 – A… read more

Figure 1: Graphical representation of AIB1Δ4 enabling DCIS invasion and metastasis.

Oncotarget

Subpopulations of AIB1-Expressing Breast Cancer Cells Enable Invasion and Metastasis

September 6, 2023

“The data in this paper suggest that even a small subpopulation of AIB1Δ4- expressing cells can enable cell invasion [...]” BUFFALO, NY- September 6, 2023 – A new editorial paper… read more

Oncotarget

Behind the Study: ER Expression Multiclonality in DCIS: Clinical & Future Insights

August 29, 2023

Dr. Mangesh A. Thorat from Guy’s Hospital in London, Queen Mary University of London, and King’s College London, describes a recent editorial he authored that was published by Oncotarget in… read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

“We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A… read more

Oncotarget

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

“Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new… read more

Figure 1: Multi-clonal ER expression in DCIS.

Oncotarget

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

August 1, 2023

“We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.” BUFFALO, NY- August 1, 2023 – A new editorial paper was published in… read more

Figure 1: An integrated representation of the multifaceted effects of progesterone in breast cancer.

Oncotarget

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

July 10, 2023

“The mechanisms underlying the observed effects of progesterone on breast cancer outcomes are unclear.” BUFFALO, NY- July 10, 2023 – A new research perspective was published in Oncotarget's Volume 14… read more

Figure 1: Upon activation by the specific agonist LY500307 ERβ binds to estrogen receptor binding elements (ERE) in regulatory regions of GPR141 and ELMO1 genes and suppresses their transcription, which in turn leads to diminished RhoC activation, reduced actin-based cell migration and metastasis.

Oncotarget

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

July 3, 2023

“The mechanism of the anti-metastatic activity of ERβ was investigated [...]” BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12,… read more